Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
108.33 USD   +2.05%
09/19Sarepta Therapeutics, Inc. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Sta..
AQ
09/15Insider Buy: Sarepta Therapeutics
MT
09/14Sarepta Therapeutics Prices Offering of $1 Billion of Convertible Notes
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about SAREPTA THERAPEUTICS, INC.
09/15Insider Buy: Sarepta Therapeutics
MT
09/14Sarepta Therapeutics Prices Offering of $1 Billion of Convertible Notes
MT
09/14Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
AQ
09/12Sarepta Therapeutics Plans $1 Billion Convertible Notes Offering; Shares Fall After Hou..
MT
09/12Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior ..
AQ
09/12Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 20th Annua..
CI
09/08Morgan Stanley Raises Price Target on Sarepta Therapeutics to $135 From $100, Keeps Equ..
MT
09/07Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program..
AQ
09/06Sarepta Therapeutics Says FDA Lifts Clinical Hold on Trial of Investigational Treatment..
MT
09/06Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Con..
AQ
09/06Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for th..
AQ
09/06Food and Drug Administration Lifts its Clinical Hold on Sarepta Therapeutics's SRP-5051..
CI
09/06Sarepta : FDA Lifts Clinical Hold on SRP-5051 in Duchenne Muscular Dystrophy
DJ
08/31Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/22Insider Buy: Sarepta Therapeutics
MT
More most relevant news
All news about SAREPTA THERAPEUTICS, INC.
09/19Sarepta Therapeutics, Inc. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
09/15Insider Buy: Sarepta Therapeutics
MT
09/14Sarepta Therapeutics Prices Offering of $1 Billion of Convertible Notes
MT
09/14Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
AQ
09/14Biopharma Credit To Receive $16 Million From Investment In Sarepta Loan
MT
09/12Sarepta Therapeutics Plans $1 Billion Convertible Notes Offering; Shares Fall After Hou..
MT
09/12Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior ..
AQ
09/12Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 20th Annua..
CI
09/08Morgan Stanley Raises Price Target on Sarepta Therapeutics to $135 From $100, Keeps Equ..
MT
09/07Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program..
AQ
More news
News in other languages on SAREPTA THERAPEUTICS, INC.
09/15Achats d'initiés : Sarepta Therapeutics
09/12Sarepta Therapeutics prévoit de proposer des obligations convertibles d'un milliard de ..
09/06Sarepta Therapeutics déclare que la FDA lève le blocage clinique de l'essai du traiteme..
09/06La Food and Drug Administration lève son blocage clinique sur le SRP-5051 de Sarepta Th..
08/22Achats d'initiés : Sarepta Therapeutics
08/08Sarepta obtient un accord de licence avec le Broad Institute pour les capsides MyoAAV a..
08/08Sarepta Therapeutics, Inc. annonce un accord de licence exclusif avec le Broad Institut..
08/02Sarepta Therapeutics réduit ses pertes au deuxième trimestre et augmente ses revenus ; ..
08/02Earnings Flash (SRPT) SAREPTA THERAPEUTICS annonce un chiffre d'affaires de 233,5 milli..
08/02Sarepta Therapeutics, Inc. Fournit des prévisions de revenus pour l'année 2022
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
09/08Morgan Stanley Raises Price Target on Sarepta Therapeutics to $135 From $100, Keeps Equ..
MT
08/10Analyst recommendations: Target, Glencore, Fidelity National Inf..
MS
08/09RBC Boosts Price Target on Sarepta Therapeutics to $182 From $160, Maintains Outperform..
MT
08/04UBS Adjusts Sarepta Therapeutics Price Target to $94 From $87, Maintains Neutral Rating
MT
08/03Guggenheim Raises Sarepta Therapeutics Price Target to $122 From $100, Maintains Buy Ra..
MT
More recommendations
Press releases
09/19Sarepta Therapeutics, Inc. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
09/14Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
AQ
09/12Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior ..
AQ
09/07Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program..
AQ
09/06Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Con..
AQ
More press releases
Upcoming event on SAREPTA THERAPEUTICS, INC.